Charles Schwab’s Usana Health Sciences USNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.81M Sell
272,208
-60,904
-18% -$1.14M ﹤0.01% 2406
2026
Q1
$5.82M Sell
333,112
-20,834
-6% -$413K ﹤0.01% 2338
2025
Q4
$6.95M Buy
353,946
+65,867
+23% +$1.37M ﹤0.01% 2305
2025
Q3
$7.94M Buy
288,079
+59,941
+26% +$1.84M ﹤0.01% 2217
2025
Q2
$6.97M Buy
228,138
+54,141
+31% +$1.54M ﹤0.01% 2180
2025
Q1
$4.69M Buy
173,997
+33,141
+24% +$1.05M ﹤0.01% 2299
2024
Q4
$5.06M Sell
140,856
-38,166
-21% -$1.43M ﹤0.01% 2329
2024
Q3
$6.79M Sell
179,022
-29,910
-14% -$1.23M ﹤0.01% 2214
2024
Q2
$9.45M Sell
208,932
-29,774
-12% -$1.37M ﹤0.01% 2071
2024
Q1
$11.6M Buy
238,706
+16,283
+7% +$797K ﹤0.01% 1917
2023
Q4
$11.9M Buy
222,423
+8,536
+4% +$432K ﹤0.01% 1888
2023
Q3
$12.5M Buy
213,887
+8,084
+4% +$505K ﹤0.01% 1795
2023
Q2
$13M Buy
205,803
+3,665
+2% +$233K ﹤0.01% 1782
2023
Q1
$12.7M Buy
202,138
+12,701
+7% +$758K ﹤0.01% 1753
2022
Q4
$10.1M Buy
189,437
+20,539
+12% +$1.11M ﹤0.01% 1846
2022
Q3
$9.47M Buy
168,898
+11,284
+7% +$746K ﹤0.01% 1873
2022
Q2
$11.4M Buy
157,614
+14,212
+10% +$1.06M ﹤0.01% 1769
2022
Q1
$11.4M Buy
143,402
+8,654
+6% +$780K ﹤0.01% 1882
2021
Q4
$13.6M Sell
134,748
-2,311
-2% -$231K ﹤0.01% 1832
2021
Q3
$12.6M Buy
137,059
+5,459
+4% +$525K ﹤0.01% 1870
2021
Q2
$13.5M Buy
131,600
+6,251
+5% +$628K ﹤0.01% 1845
2021
Q1
$12.2M Sell
125,349
-11,575
-8% -$1.05M ﹤0.01% 1842
2020
Q4
$10.6M Buy
136,924
+3,909
+3% +$302K ﹤0.01% 1839
2020
Q3
$9.8M Sell
133,015
-3,299
-2% -$265K ﹤0.01% 1710
2020
Q2
$10M Sell
136,314
-1,747
-1% -$137K ﹤0.01% 1654
2020
Q1
$7.97M Buy
138,061
+15,249
+12% +$1.06M ﹤0.01% 1588
2019
Q4
$9.65M Buy
122,812
+6,079
+5% +$448K 0.01% 1686
2019
Q3
$7.98M Sell
116,733
-64,238
-35% -$4.31M ﹤0.01% 1731
2019
Q2
$14.4M Buy
180,971
+4,254
+2% +$337K 0.01% 1375
2019
Q1
$14.8M Buy
176,717
+42,436
+32% +$4.43M 0.01% 1315
2018
Q4
$15.8M Buy
134,281
+2,983
+2% +$345K 0.01% 1139
2018
Q3
$15.8M Buy
131,298
+3,379
+3% +$419K 0.01% 1319
2018
Q2
$14.8M Sell
127,919
-272
-0.2% -$29.8K 0.01% 1312
2018
Q1
$11M Buy
128,191
+44,707
+54% +$3.46M 0.01% 1424
2017
Q4
$6.18M Sell
83,484
-1,373
-2% -$91.8K ﹤0.01% 1803
2017
Q3
$4.9M Sell
84,857
-7,204
-8% -$426K ﹤0.01% 1891
2017
Q2
$5.9M Sell
92,061
-32,900
-26% -$2.03M 0.01% 1713
2017
Q1
$7.2M Buy
124,961
+4,297
+4% +$257K 0.01% 1544
2016
Q4
$7.38M Buy
120,664
+52,198
+76% +$3.4M 0.01% 1475
2016
Q3
$4.74M Buy
68,466
+3,380
+5% +$223K 0.01% 1690
2016
Q2
$3.63M Sell
65,086
-10,526
-14% -$635K ﹤0.01% 1765
2016
Q1
$4.59M Sell
75,612
-3,170
-4% -$187K 0.01% 1564
2015
Q4
$5.03M Sell
78,782
-14,694
-16% -$953K 0.01% 1513
2015
Q3
$6.26M Buy
93,476
+4,266
+5% +$302K 0.01% 1323
2015
Q2
$6.1M Buy
89,210
+3,384
+4% +$215K 0.01% 1423
2015
Q1
$4.77M Buy
85,826
+11,122
+15% +$570K 0.01% 1539
2014
Q4
$3.83M Buy
74,704
+26,266
+54% +$1.29M 0.01% 1633
2014
Q3
$1.78M Buy
48,438
+6,078
+14% +$219K ﹤0.01% 2025
2014
Q2
$1.66M Buy
42,360
+13,096
+45% +$486K ﹤0.01% 2081
2014
Q1
$1.1M Buy
29,264
+840
+3% +$29.3K ﹤0.01% 2238
2013
Q4
$1.07M Buy
28,424
+1,008
+4% +$38.6K ﹤0.01% 2233
2013
Q3
$1.22M Buy
27,416
+1,358
+5% +$54.5K ﹤0.01% 2125
2013
Q2
$950K Buy
+26,058
New +$792K ﹤0.01% 2191

Other funds holding USNA

Charles Schwab's USNA Position: Q2 2026 in Review

Charles Schwab reduced its Usana Health Sciences (USNA) stake by 18% in Q2 2026, selling an estimated $1.14M and leaving 272,208 shares worth $5.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2406.

Charles Schwab first reported a position in USNA in Q2 2013 and has held it in 53 quarters since. The position peaked at $15.8M in Q3 2018. 138 funds tracked by Wall St. Rank hold USNA as of Q2 2026.

  • Charles Schwab held 272,208 shares of Usana Health Sciences worth $5.81M as of Q2 2026.
  • Charles Schwab sold 60,904 Usana Health Sciences shares in Q2 2026, an estimated $1.14M.
  • Usana Health Sciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2406 holding.
  • Charles Schwab first reported a position in Usana Health Sciences in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Usana Health Sciences position peaked at $15.8M in Q3 2018.
  • 138 funds tracked by Wall St. Rank held Usana Health Sciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.